317 related articles for article (PubMed ID: 14633724)
1. Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis.
Lanson NA; Friedlander PL; Schwarzenberger P; Kolls JK; Wang G
Cancer Res; 2003 Nov; 63(22):7936-41. PubMed ID: 14633724
[TBL] [Abstract][Full Text] [Related]
2. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
3. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression.
Kuppuswamy M; Spencer JF; Doronin K; Tollefson AE; Wold WS; Toth K
Gene Ther; 2005 Nov; 12(22):1608-17. PubMed ID: 16034456
[TBL] [Abstract][Full Text] [Related]
5. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma].
Song Y; Shen K; Yu JR
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2919-24. PubMed ID: 18261307
[TBL] [Abstract][Full Text] [Related]
6. Potent antitumor effect of TRAIL mediated by a novel adeno-associated viral vector targeting to telomerase activity for human hepatocellular carcinoma.
Wang Y; Huang F; Cai H; Zhong S; Liu X; Tan WS
J Gene Med; 2008 May; 10(5):518-26. PubMed ID: 18338833
[TBL] [Abstract][Full Text] [Related]
7. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
[TBL] [Abstract][Full Text] [Related]
8. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters.
Majumdar AS; Hughes DE; Lichtsteiner SP; Wang Z; Lebkowski JS; Vasserot AP
Gene Ther; 2001 Apr; 8(7):568-78. PubMed ID: 11319624
[TBL] [Abstract][Full Text] [Related]
9. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
[TBL] [Abstract][Full Text] [Related]
11. Suppression of cancer growth in mice by adeno-associated virus vector-mediated IFN-beta expression driven by hTERT promoter.
He LF; Wang YG; Xiao T; Zhang KJ; Li GC; Gu JF; Chu L; Tang WH; Tan WS; Liu XY
Cancer Lett; 2009 Dec; 286(2):196-205. PubMed ID: 19564073
[TBL] [Abstract][Full Text] [Related]
12. Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer.
Ryan PC; Jakubczak JL; Stewart DA; Hawkins LK; Cheng C; Clarke LM; Ganesh S; Hay C; Huang Y; Kaloss M; Marinov A; Phipps SS; Reddy PS; Shirley PS; Skripchenko Y; Xu L; Yang J; Forry-Schaudies S; Hallenbeck PL
Cancer Gene Ther; 2004 Aug; 11(8):555-69. PubMed ID: 15232601
[TBL] [Abstract][Full Text] [Related]
13. Telomerase-specific replication-selective virotherapy for human cancer.
Kawashima T; Kagawa S; Kobayashi N; Shirakiya Y; Umeoka T; Teraishi F; Taki M; Kyo S; Tanaka N; Fujiwara T
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):285-92. PubMed ID: 14734481
[TBL] [Abstract][Full Text] [Related]
14. Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter.
Jacob D; Davis J; Zhu H; Zhang L; Teraishi F; Wu S; Marini FC; Fang B
Clin Cancer Res; 2004 May; 10(10):3535-41. PubMed ID: 15161713
[TBL] [Abstract][Full Text] [Related]
15. [Construction of autocatalytic caspase-3 driven by amplified human telomerase reverse transcriptase promoter and its enhanced efficacy of inducing apoptosis in human ovarian carcinoma].
Song Y; Shen K; He CX
Zhonghua Fu Chan Ke Za Zhi; 2007 Sep; 42(9):617-22. PubMed ID: 17983518
[TBL] [Abstract][Full Text] [Related]
16. Concomitant use of Ad5/35 chimeric oncolytic adenovirus with TRAIL gene and taxol produces synergistic cytotoxicity in gastric cancer cells.
Chen L; Chen D; Gong M; Na M; Li L; Wu H; Jiang L; Qian Y; Fang G; Xue X
Cancer Lett; 2009 Nov; 284(2):141-8. PubMed ID: 19447545
[TBL] [Abstract][Full Text] [Related]
17. Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter.
Komata T; Kondo Y; Kanzawa T; Hirohata S; Koga S; Sumiyoshi H; Srinivasula SM; Barna BP; Germano IM; Takakura M; Inoue M; Alnemri ES; Shay JW; Kyo S; Kondo S
Cancer Res; 2001 Aug; 61(15):5796-802. PubMed ID: 11479218
[TBL] [Abstract][Full Text] [Related]
18. hTERT-promoter-dependent oncolytic adenovirus enhances the transduction and therapeutic efficacy of replication-defective adenovirus vectors in pancreatic cancer cells.
Onimaru M; Ohuchida K; Mizumoto K; Nagai E; Cui L; Toma H; Takayama K; Matsumoto K; Hashizume M; Tanaka M
Cancer Sci; 2010 Mar; 101(3):735-42. PubMed ID: 20059477
[TBL] [Abstract][Full Text] [Related]
19. Dual promoter-controlled oncolytic adenovirus CG5757 has strong tumor selectivity and significant antitumor efficacy in preclinical models.
Li Y; Idamakanti N; Arroyo T; Thorne S; Reid T; Nichols S; VanRoey M; Colbern G; Nguyen N; Tam O; Working P; Yu DC
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8845-55. PubMed ID: 16361574
[TBL] [Abstract][Full Text] [Related]
20. Low-dose etoposide enhances telomerase-dependent adenovirus-mediated cytosine deaminase gene therapy through augmentation of adenoviral infection and transgene expression in a syngeneic bladder tumor model.
Shieh GS; Shiau AL; Yo YT; Lin PR; Chang CC; Tzai TS; Wu CL
Cancer Res; 2006 Oct; 66(20):9957-66. PubMed ID: 17047058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]